Cargando…
Methods for Identifying Patients with Tropomyosin Receptor Kinase (TRK) Fusion Cancer
NTRK gene fusions affecting the tropomyosin receptor kinase (TRK) protein family have been found to be oncogenic drivers in a broad range of cancers. Small molecule inhibitors targeting TRK activity, such as the recently Food and Drug Administration-approved agent larotrectinib (Vitrakvi®), have sho...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Netherlands
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7297824/ https://www.ncbi.nlm.nih.gov/pubmed/31256325 http://dx.doi.org/10.1007/s12253-019-00685-2 |